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candidiasis and candidemia are fre-
quently encountered in the
nosocomial setting particularly in the
intensive care unit (ICU). Objective
and methods: To review the current
management of invasive candidiasis
and candidemia in non-neutropenic
adult ICU patients based on a review
of the literature and an European
expert panel discussion. Results and
conclusions: Empiric and directed
treatment for invasive candidiasis are
predicated on the hemodynamic sta-
tus of the patient. Unstable patients
may benefit from broad-spectrum
antifungal agents, which can be nar-
rowed once the patient has stabilized
and the identity of the infecting spe-
cies is established. In stable patients,
a more classical approach using
fluconazole may be satisfactory pro-
vided that the patient is not colonized
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with fluconazole resistant strains or
there has been recent past exposure to
an azole (\30 days). In contrast, pre-
emptive therapy is based on the
presence of surrogate markers.
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CAGT Candida albicans germ tube
CI Colonization index
DLY Discounted life year
FIO2 Fraction of inspired oxygen
HwP1 Hyphal wall protein 1
ICU Intensive care unit
INR International normalized
ratio
MAP Mean arterial blood pressure
OR Odds ratio
PaO2 Partial pressure of arterial
oxygen
PCR Polymerize chain reaction




SICU Surgical intensive care unit
SIRS Systemic inflammatory
response syndrome
SvO2 Mixed venous oxygen
saturation
WBC White blood cell
Introduction
The treatment of invasive candidiasis and candidemia can
be schematically described as prophylactic, pre-emptive,
empiric or curative. Prophylactic treatment covers all the
situations where the patient is not infected and lacks the
signs and symptoms of infection. In pre-emptive treat-
ment, based on evaluation of the patient’s risk factors
combined with positive surrogate markers of infection,
the patient is deemed to be at significant risk of being
infected and this increased risk justifies a treatment; the
goal is to decrease Candida-related mortality. Empiric
therapy describes individuals with symptoms of infection
with no obvious source who merit therapy based on
clinical grounds. In many studies the lines between the
latter two groups of treatment are not always very clear.
Finally, curative treatment focuses on a microbiologically
documented pathogen.
The need for appropriate and early treatment
Appropriate therapy is a major factor associated with a
good prognosis in fungal infection. In a 5-year study, 207
patients were diagnosed with invasive candidiasis and
candidemia of which 52% were due to Candida albicans
[1], 64 (32%) were given empirical therapy, of which 51
(26%) was deemed adequate. Adequate empirical therapy
was independently associated with a reduced risk of death
(crude mortality rate 27 vs. 46%; OR 0.46). A study
performed in 28 hospitals in Spain showed that early
therapy (treatment started within the 48 h after the onset
of candidemia) was associated with a higher probability
of survival [2]. In another study, Garey et al. [3] also
emphasized the importance of the timing of treatment. In
this study, mortality rates were lower for patients who
began therapy on day 0 (15%) compared to day 1 (24%),
day 2 (37%) or later (41%). The delay was defined as the
difference between blood drawing and treatment onset. A
comparable result was found by Morrell et al. [4]: in this
study, the authors showed that administration of anti-
fungal treatment 12 h after having the first positive blood
sample for culture was an independent marker of hospital
mortality. In non-neutropenic critically ill patients with
sepsis, inappropriate empirical antimicrobial therapy was
frequently associated with presence of invasive fungal
infection and contributed to an increased mortality rate
[5]. Kumar et al. also demonstrated increased mortality
rates in patients with fungal sepsis and shock associated
with delays in the initiation of therapy: every hour delay
was associated with a 12% decreased probability of sur-
vival [1, 6].
Prophylactic antifungal treatment in the ICU
Candida spp live as commensals in the gut lumen and on
cutaneous surfaces. As has been previously discussed,
there is a strong link between Candida colonization and
invasive candidiasis; therefore it would seem clinically
relevant to decrease the fungal load with an antifungal
drug. Since morbidity and mortality rates in patients with
invasive candidiasis infections are high, the use of pro-
phylaxis seems very attractive. This prophylactic strategy
has been validated in different subsets of patients such
as neutropenic patients with hematological malignancies,
or after bone marrow transplant [7]. In the ICU, this
approach remains under discussion. There is a need to
better identify the ICU patient profile that could benefit
from prophylactic antifungal therapy as the following
studies illustrates.
In a medical/SICU, Garbino et al. [8] compared two
groups of patients with selective digestive decontamina-
tion (SDD) with or without fluconazole (100 mg daily).
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Their results showed that 90% of candidemia episodes
occurred in the placebo group, but the crude mortality rate
remained unchanged. In selected high-risk surgical
patients undergoing relaparotomy for bowel perforation
or suture leakage, Eggimann et al. [9] used intravenous
fluconazole prophylaxis and showed prevention of both
colonization and invasive intra-abdominal invasive can-
didiasis. An important observation in this study,
compared to the previously described Garbino trial, is the
dose of fluconazole used (400 mg daily), which was a
curative rather than a prophylactic dose. Moreover, it is
difficult to know, from the type of patients recruited,
whether it was genuine prophylactic treatment as the
study mostly involved a high-risk surgical population.
Hence applying current criteria the study may be better
described as evaluating pre-emptive or empirical treat-
ment. This approach is further supported by data from
Pelz et al. [10] who showed in a prospective study of 159
ICU patients that fungal burden was strongly associated
with infection. In this trial, having two or more sites
positive in a single day was associated with an odd ratio
of 8.2. Recently, Manzoni et al. [11] showed a significant
decrease of invasive candidiasis with fluconazole pro-
phylaxis, although this was in neonates; no effect on
mortality was observed.
A systematic review of published antifungal prophy-
laxis studies carried out in the ICU setting evaluated
whether systematic antifungal therapy could decrease
morbidity and mortality [12]. Prophylaxis with an azole
was associated with a reduced rate of candidemia, as well
as a decrease of Candida-attributable mortality and
overall mortality rates. While the systematic review was
based on highly divergent studies, addressing different
methodologies, different patient populations and using
different antifungal therapy, the conclusions of this
review nevertheless lend some support to the hypothesis
that prophylaxis could be of benefit in selected subsets of
patients. The results of five meta-analyses on this subject
are nicely summarized in a review paper by Pfaller et al.
[13] and support a policy of prophylaxis in selected
patients, with a reduction of the risk of invasive form by
50 to 80%. The effect was however, less clear on mor-
tality or on the emergence of azole-resistant Candida
species. The selection of patient groups who will benefit
from prophylaxis is still unclear, and there is a need for
additional data.
Prophylactic therapy should also be scrutinized in
relation to potential deleterious consequences such as
selection of resistant strains and drug-related toxicity
[14]. Several studies have suggested a potential link
between prophylactic use of fluconazole and an increase
in resistance or selection of azole-resistant species.
Bassetti et al. [15] observed this phenomenon during a
5-year study from Brazil. Interestingly, although not
strictly confined to ICU patients, a retrospective study
attempted to describe all cases of nosocomial candidemia
that occurred in patients receiving at least 3 days of
systemic antifungal drugs [16]. Non-albicans species,
mainly C. parapsilosis, and C. tropicalis, the two most
prevalent non-albicans Candida species in this country,
caused 75% of these infections. Of the 20 patients
studied, 40% had cancer, and when compared to controls,
risk factors were mucositis, longer stay in the ICU,
longer periods of hyperalimentation, mechanical venti-
lation, urinary catheter, and use of broad-spectrum
antibiotics. Similarly, one case report documented a
C. glabrata isolate with a specific profile of resistance in
a critically ill patient, that was resistant to both ampho-
tericin B and caspofungin [17]. In a retrospective
analysis of two ICU patient cohorts, Rocco et al. [18]
analyzed the effect of fluconazole administration on
Candida sensitivity. As use of this antifungal agent
increased, an increase in Candida spp that were resistant
to fluconazole was observed.
Empiric and pre-emptive treatments
Several drugs have been tested in these settings and could
therefore be proposed for treatment. A retrospective audit
of 225 SICU patients receiving antifungal therapy showed
that fluconazole was the most frequently prescribed
antifungal drug (1,846 patient-days), followed by
amphotericin B (251 patient-days) [19]. These data are
not representative of current usage patterns as the study
was carried out between 2001 and 2002. The drugs were
prescribed empirically (44%), for pre-emptive therapy in
colonized patients (43%) or in those with candidiasis
(12%). The authors concluded that efforts to identify
patients who warrant pre-emptive antifungal therapy for
invasive candidiasis could dramatically change antifungal
prescribing patterns in this setting. However, there are no
substantiating data from randomized trials to support the
empiric or pre-emptive use of antifungal agents in the
ICU setting.
Piarroux et al. [20] tried to assess the efficacy of pre-
emptive antifungal therapy in preventing proven candi-
diasis in critically ill surgical patients. In a total of 933
patients, they evaluated, as a primary endpoint, the fre-
quency of proven candidiasis within a prospective period
during which patients with a corrected colonization index
C0.4 received early pre-emptive antifungal therapy with
fluconazole. Candida infections occurred more frequently
in the control cohort (7 vs. 3.8%; P = 0.03). The inci-
dence of SICU-acquired proven candidiasis significantly
decreased from 2.2 to 0%. The authors concluded that
a targeted pre-emptive strategy may be effective in
preventing acquisition of proven candidiasis in SICU
patients.
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Treatment of documented infection
In recent guidelines the drugs proposed as first-line ther-
apy have usually been selected based on the clinical status
of the patient [14, 21]. The reason for such risk-based
strategy is the assumption that critically-ill patients may
benefit most from a highly-active therapy, and that there is
no room for failure. If narrow-spectrum antifungals are
chosen they may not cover the pathogen involved. This
hypothesis may be supported by the recent studies sug-
gesting that early institution of adequate antifungal
therapy may significantly reduce mortality in patients with
candidemia, as described above [3, 4, 6]. Thus although
this is not evidenced based medicine, retrospective data
point to a differentiation between hemodynamically stable
from hemodynamically unstable patients. It can be
assumed that a clear line can be drawn for patients in
septic shock, an intermediate risk group should be pro-
posed for patients with severe sepsis. It seems appropriate
therefore, to first describe the specific definitions before
discussing the treatment itself.
Systemic inflammatory response syndrome, sepsis,
severe sepsis and septic shock
After its initial definition in 1991, the diagnosis of sepsis
was revisited in 2003 and the list of clinical signs and
symptoms was expanded, reflecting bedside experience
[22]. The definition of a hemodynamically unstable
patient with sepsis needs to be applied according to this
classification. Four stages are differentiated: systemic
inflammatory response syndrome (SIRS), sepsis, severe
sepsis (with organ dysfunction), and septic shock.
Sepsis is defined by the presence of both infection and
SIRS. The diagnostic criteria for sepsis are summarized in
the Electronic supplement material. Severe sepsis refers
to sepsis complicated by organ dysfunction, and septic
shock represents a state of acute circulatory failure
characterized by persistent arterial hypotension despite
adequate volume resuscitation in the absence of other
causes of hypotension.
A patient with septic shock is clearly characterized as
a hemodynamically unstable patient; SIRS and sepsis
patients however, do not fit this definition. Most of the
debate or controversy regarding the identification of
hemodynamically unstable patients focuses on the patient
with severe sepsis, i.e. a patient with organ failure. They
are at higher risk of progressing to septic shock if treat-
ment is inadequate. Although they do not completely fit
the definition of ‘hemodynamically unstable’, it may be
prudent to classify these patients as high-risk and there-
fore propose a line of treatment identical to that for the
well-defined unstable group using additional markers like
plasma lactate.
The available drugs and their main treatment
outcomes in the ICU
Treatment of invasive candidiasis and candidemia has
changed significantly in recent years due to a growing
number of newly available agents, and the resulting
modification of guidelines. Case series, published in the
1990s, used mainly fluconazole and amphotericin B and
showed no difference between the two groups [2]. The
main concern with amphotericin B was its toxicity.
Currently available drugs to treat invasive candidiasis
and candidemia include amphotericin B and its derived
lipid formulations, fluconazole, voriconazole, caspofun-
gin, anidulafungin and micafungin. The focus of this
review will be on data from the most recently introduced
agents—caspofungin, anidulafungin and voriconazole.
Most Candida spp are usually susceptible to these agents,
but resistance has been described either naturally or after
previous exposure to the drugs. For example, C. glabrata,
C. krusei, C. parapsilosis and C. lusitaniae can present
resistance to the primary agent or require a dosage
increase (Table 1).
Echinocandins are the most recently introduced class
of antifungal drugs. This new class includes caspofungin,
anidulafungin, both now available in Europe, and mica-
fungin, which is not yet marketed. Echinocandins are
fungicidal drugs that are active against both C. albicans


























C. albicans 0.06 0.25 0.13 1 0.25 2 0.03 0.06 0.5 0.5 0.03 0.03
C. glabrata 0.13 0.5 0.13 0.13 8 32 0.25 1 0.5 1 0.03 0.13
C. parapsilosis 0.1 0.5 0.13 0.13 1 2 0.03 0.06 2 2 2 2
C. tropicalis 0.13 0.5 0.13 0.5 0.5 16 0.06 2 0.5 1 0.03 0.13
C. krusei 0.25 0.5 4 32 32 [64 0.5 1 1 2 0.06 0.13
C lusitaniae 0.13 0.5 0.13 0.13 0.5 2 0.03 0.06 1 2 0.06 0.25
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and non-albicans species. Caspofungin has been shown to
be as effective as, and better tolerated than, conventional
amphotericin B in patients with invasive candidiasis [23].
This improvement in tolerance could be important in the
management of the ICU patient, particularly in those with
renal failure. Evaluation of this drug in ICU patients has
been carried out in a post hoc analysis of the Mora-Duarte
trial [23] specifically in relation to risk factors and out-
come. The authors found that even after accounting for
differences in the Apache II score, patients starting the
study drug in the ICU were more likely to die than those
starting it outside the ICU [24]. The all-cause mortality
among candidemic ICU patients was 45%. There was no
statistically significant difference in all-cause or Candida-
attributable mortality rate between patients treated with
either caspofungin or amphotericin B, but the incidence of
drug-related adverse events and of nephrotoxicity was
significantly lower in the caspofungin group. These
findings suggest that caspofungin could be an attractive
choice in ICU patients in whom renal failure or prior
azole exposure limit the use of other antifungal agents. It
must however be underlined that, beside toxicity, the
efficacy between the two drugs showed no significant
differences. Pappas et al. [25] compared two dosages of
micafungin to caspofungin. The results showed that
100 mg daily and 150 mg daily were non-inferior to a
standard dosage of caspofungin for the treatment of
candidemia. The authors did not find any statistical dif-
ference in mortality, relapsing and emergent infection or
adverse events between the drugs. Of note, whereas mi-
cafungin has been licensed, its approved use in Europe is
restricted to cases where other antifungals are not
appropriate, in view of its potential risk for the develop-
ment of liver tumors. Table 2 summarizes the main
results of the studies involving echinocandins.
It has been shown, mostly through study of antibiotics,
that the pharmacokinetic/pharmacodynamic profile of
ICU patients is different from that of non-ICU controls,
with large variations in the volume of distribution and
renal clearance. Nguyen et al. [26] analyzed the factors
influencing caspofungin concentrations in ICU patients;
they showed that body weight \75 kg and albumin con-
centration [23.6 g/l was associated with higher levels of
caspofungin than predicted.
Anidulafungin has recently been studied in a ran-
domized double blind trial of treatment for invasive
candidiasis [21]. In this study, anidulafungin was com-
pared with fluconazole, with the primary efficacy analysis
assessing the global response at the end of intravenous
therapy. At this endpoint, treatment was successful in
75.6% of patients treated with anidulafungin, as compared
with 60.2% of those treated with fluconazole (P = 0.009).
In this population, 21% in the anidulafungin group and
17% in the fluconazole group had an Apache II score[20.
Overall, the authors concluded that anidulafungin was not
inferior to and suggested to be more efficacious than
fluconazole for the primary treatment of candidemia, with
a safety profile similar to that of fluconazole. The authors
also commented that the success rate at the end of intra-
venous anidulafungin in this trial was similar to that
reported in a study evaluating caspofungin in the primary
treatment of invasive candidiasis [23].
There are also new azoles that should be considered
for therapy of invasive candidiasis in ICU patients. Vo-
riconazole is recommended as first-line of therapy in
invasive aspergillosis, but several studies suggest a
potential role in candidiasis. Ostrosky-Zeichner et al. [27]
showed that voriconazole was efficient as a salvage
therapy in this indication. In a randomized study in non-
neutropenic patients with candidemia, voriconazole was
compared to a regimen of amphotericin B followed by
fluconazole [28]. Half of the patients in each group were
in the ICU. The results showed that voriconazole was as
effective as the control regimen in the treatment of can-
didemia, with significantly fewer side-effects. In this
study, amphotericin B was only administered for a med-
ian of 4 days, underlining that even short courses of this
drug could be associated with significant adverse effects.
One limitation regarding extrapolation of voriconazole
use for ICU patients is that the i.v. formulation of


































































mITT Modified intention to treat, EOT end of treatment, AE adverse event, LFAB lipid formulations of amphotericin B
a Success evaluated at the end of IV therapy
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voriconazole is contra-indicated in patients with a creat-
inine clearance of \50 ml/min.
Antifungal therapy based on patient’s clinical status
A treatment algorithm for invasive candidiasis was
recently proposed by Spellberg et al. [29]. They proposed
the hemodynamic status of the patient as the main crite-
rion for selection of pharmacological intervention
(Fig. 1).
In hemodynamically stable patients without organ
dysfunction, fluconazole is a reasonable choice for
empiric therapy or microbiologically documented infec-
tion, based on its highly favorable safety profile and low
costs [30]. Alternative drugs to be considered are echi-
nocandins (caspofungin or anidulafungin), voriconazole,
or amphotericin B (deoxycholate or liposomal). The
duration of treatment should be continued for 2 weeks
after the last positive culture.
However, if the likelihood of azole-resistant species is
high, based on local resistance reports, if the patient
is colonized with azole-resistant species, or recently
exposed to an azole (within 30 days) as prophylactic
treatment, fluconazole should be avoided and the use of
echinocandins or polyenes is preferred.
In contrast, patients who are hemodynamically
unstable with septic shock or who have signs of severe
sepsis require potent therapy, with a broad-spectrum
agent that has a minimum toxicity. To achieve this aim,
echinocandins are a preferred first choice (caspofungin
or anidulafungin), as has been supported by the results
of the Reboli study [21]. Alternatively, lipid formula-
tions of amphotericin B (LFAB) may be used in unstable
patients. Conventional amphotericin B is associated with
a high risk of side effects e.g. renal failures and can
therefore not be recommended in critically ill patients.
Transition from an echinocandin or LFAB to fluconazole
or voriconazole is recommended once patients are clin-
ically stabilized and the isolate has been confirmed to be
azole-susceptible.
Combination therapy
The poor prognosis attributed to Candida sepsis in the
ICU has provoked much debate on the potential beneficial
effect of combination therapy, but currently few studies
have been conducted in this area. In a study comparing
fluconazole with amphotericin B versus fluconazole
alone, the combination resulted in a better response rate in
the combination group, although associated with signifi-
cant amphotericin B toxicity [31]. Flucytosine is another
classical agent used in combined therapy; because of its
ability to penetrate the blood brain barrier, this drug is
often added to amphotericin in cerebral, ocular and
meningeal localizations [32, 33]. Over many years dif-
ferent studies have described multiple antifungal
combinations for the treatment of invasive fungal infec-
tions. The scientific rationale to support the use of
combination therapy is based on the hypothesis that the
infecting pathogen is more effectively treated if drugs
with different mechanisms of action are combined.
Recently, one study on Aspergillus infection in transplant
patients obtained better results with voriconazole plus
caspofungin compared with lipid formulation of ampho-
tericin B [34]. To date, the use of combination antifungal
therapy in patients with invasive candidiasis is not rec-
ommended and further studies are required.
Cost-effectiveness of these approaches
In a cost-effectiveness analysis concerning ICU patients,
Golan et al. [35] showed that in suspected infections that
have not responded to antibiotic treatment, empirical
fluconazole could reduce mortality at an acceptable cost.
They also concluded that empirical strategies are not
justified in low-risk patients. Recent work by Chen et al.
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Fig. 1 Algorithm summarizing the practical treatment of docu-
mented candidiasis in the ICU. LFAB Liposomal form of
amphotericin B
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of fluconazole in ICU patients suspected to have invasive
candidiasis. The rationale for this approach was the
observed increasing percentage of non-albicans Candida
with a decreased susceptibility to fluconazole. In this
study, high-dose fluconazole was the more effective but
also more expensive treatment strategy compared to low-
dose therapy, with a cost-effectiveness rate of $55,526 per
discounted life year (DLY) saved. The authors concluded
that this strategy should reduce mortality at an acceptable
cost. However, it should be noted that these models have
not taken into account the results of the recent study
suggesting a significantly better outcome with anidula-
fungin compared with fluconazole [21] which would
justify a formal cost-effectiveness analysis comparing
anidulafungin with fluconazole-based strategies.
Catheter management in the ICU patient
It has been known for a long time that intravascular
catheters are significant risk factors for the development
of candidemia [37, 38]. The initial retrospective study by
Rex et al. [39] suggested the need to remove all intra-
vascular catheters in candidemia. In the subset of patients
who had a catheter in place at the time of their first
positive blood culture, removal and replacement of all
lines was associated with a reduction in the mean duration
of candidemia. In a study performed in cancer patients,
central venous catheter removal was only effective in
improving the response to antifungal agents when the
candidemia could be related to the catheter [40]. In ICU
patients, however, it seems reasonable to propose catheter
exchange in all patients with candidemia whenever
logistically feasible.
Pharmacokinetics profile
The pharmacokinetics properties of an antimicrobial
agent are essential to promote microbiological eradication
and clinical efficacy. ICU patients with invasive Candida
infections present special characteristics: higher disease
severity, organ dysfunction (particularly in case of car-
diovascular, renal and hepatic failure), co-morbidities and
drugs. In these patients, not only plasma concentrations
but also tissue penetration of the antifungal drug is crucial
to obtain favorable clinical and microbiological results.
The pharmacokinetic analyses of echinocandins suggest
that these drugs behave like concentration-dependent
molecules, thus high intermittent dosing may be desirable
for the treatment of invasive candidiasis. The potential
limitations of high drug doses include a paradoxical
decrease in microbial kill (the eagle effect) as well as the
toxicity of high intermittent doses [41]. Finally the main
difference between caspofungin, micafungin, and anidu-
lafungin relates on the elimination profile, the half life
and the distribution volume [42]. Additional pharmaco-
kinetics studies are needed in ICU patients [43].
Conclusion
The choice of empiric therapy or therapy for documented
infection is dependent on the hemodynamic status of the
patient, and will probably involve the use of drugs from
the echinocandin family if the patient is unstable. On the
other hand, a stable patient can be treated with azole as
long as known colonization with a fluconazole-resistant
strain, local epidemiology or previous exposure to this
drug does not demand a broader antifungal spectrum.
Current guidelines have to be re-evaluated as the avail-
ability of new molecules, new tests and new diagnostic
procedures, raise important questions that have to be
answered, specifically in this subset of patients.
Expert opinion
Intensive care unit patients represent a diverse population
for the treatment of invasive candidiasis; the clinical
presentation and vital prognosis are usually the key issues
of the treatment. According to the current literature, the
use of prophylactic therapy in high-risk individuals such
as surgical ICU patients warrants consideration. In doc-
umented Candida infection and those patients highly
suspected of having invasive candidiasis, the choice of
therapy depends on the hemodynamic status of the patient
and previous azole exposure or resistance. In the hemo-
dynamically unstable patient, a broad spectrum fungicidal
drug like an echinocandin is the preferred choice. Since
the diagnosis of invasive candidiasis occurs in the late
phase of the evolution of the disease (either a positive
blood culture, or a high colonization index for example),
the main challenge for the future is to elaborate diagnostic
methods that will give us the opportunity to identify the
patients affected by these infections earlier in the course
of the disease. Moreover, beyond diagnosis correct iden-
tification of the pathogen and its associated resistance
pattern needs to be improved. Finally, in ICU patients,
combination antifungal therapy remains to be explored.
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